XLotus Therapeutics

XLotus Therapeutics is a preclinical-stage biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for oncology. The company specializes in targeting the ubiquitin-proteasome system, specifically focusing on the concept of synthetic lethality. Its lead program is a potent and selective inhibitor of Ubiquitin Specific Peptidase 1 (USP1), designed to treat cancers with DNA damage response deficiencies. XLotus aims to address unmet medical needs in patients with BRCA-mutant tumors, such as ovarian and breast cancers, who may have developed resistance to existing therapies. Headquartered in Suzhou, China, the company is backed by prominent venture capital firms including 6 Dimensions Capital. The management team consists of industry veterans with extensive experience in drug discovery and clinical development.